https://www.selleckchem.com/pr....oducts/Pemetrexed-di
6 months (95% confidence interval [CI], 8.0-9.3) and 7.4 months (95% CI, 6.8-8.5), respectively; for those with ECOG PS 0-1, median OS was 10.8 months (95% CI, 9.8-11.8) and 8.7 months (95% CI, 7.6-9.7), respectively. In both cohorts, programmed death ligand 1 expression≥ 1% and ECOG PS 0-1 were associated with longer OS (P .05); the number of prior lines of therapy and age≥ 75 years had no significant association with OS. This study confirmed the effectiveness of nivolumab monotherapy for previously treated advanced NSC
Like
Comment
Share
